Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Public ClinicalTrials.gov record NCT00588900. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cediranib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving irinotecan together with cediranib may kill more tumor cells. PURPOSE: This phase II clinical trial is studying how well giving irinotecan together with cediranib works in treating patients with metastatic colorectal cancer that did not respond to previous oxaliplatin, fluoropyrimidine, and bevacizumab.
Study identification
- NCT ID
- NCT00588900
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 5 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2008 (Type not available)
- Primary completion
- May 2010 (Actual)
- Completion
- Nov 2011 (Actual)
- Last update posted
- Apr 5, 2017
2008 – 2011
United States locations
- U.S. sites
- 31
- U.S. states
- 9
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Evanston Hospital | Evanston | Illinois | 60201-1781 | — |
| Elkhart Clinic, LLC | Elkhart | Indiana | 46514-2098 | — |
| Elkhart General Hospital | Elkhart | Indiana | 46515 | — |
| Fort Wayne Medical Oncology and Hematology | Fort Wayne | Indiana | 46845 | — |
| Howard Community Hospital | Kokomo | Indiana | 46904 | — |
| Center for Cancer Therapy at LaPorte Hospital and Health Services | La Porte | Indiana | 46350 | — |
| CCOP - Northern Indiana CR Consortium | South Bend | Indiana | 46601 | — |
| Memorial Hospital of South Bend | South Bend | Indiana | 46601 | — |
| Michiana Hematology-Oncology, PC - South Bend | South Bend | Indiana | 46601 | — |
| Saint Joseph Regional Medical Center | South Bend | Indiana | 46617 | — |
| South Bend Clinic | South Bend | Indiana | 46617 | — |
| Hematology Oncology Associates of the Quad Cities | Bettendorf | Iowa | 52722 | — |
| Holden Comprehensive Cancer Center at University of Iowa | Iowa City | Iowa | 52242-1002 | — |
| Lakeland Regional Cancer Care Center - St. Joseph | Saint Joseph | Michigan | 49085 | — |
| Lakeside Cancer Specialists, PLLC | Saint Joseph | Michigan | 49085 | — |
| Ellis Fischel Cancer Center at University of Missouri - Columbia | Columbia | Missouri | 65203 | — |
| Cancer Resource Center - Lincoln | Lincoln | Nebraska | 68510 | — |
| CCOP - Missouri Valley Cancer Consortium | Omaha | Nebraska | 68106 | — |
| Immanuel Medical Center | Omaha | Nebraska | 68122 | — |
| Alegant Health Cancer Center at Bergan Mercy Medical Center | Omaha | Nebraska | 68124 | — |
| Creighton University Medical Center | Omaha | Nebraska | 68131-2197 | — |
| New Hampshire Oncology - Hematology, PA at Payson Center for Cancer Care | Concord | New Hampshire | 03301 | — |
| New Hampshire Oncology - Hematology, PA - Hooksett | Hooksett | New Hampshire | 03106 | — |
| Lakes Region General Hospital | Laconia | New Hampshire | 03246 | — |
| CCOP - Hematology-Oncology Associates of Central New York | East Syracuse | New York | 13057 | — |
| Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill | Chapel Hill | North Carolina | 27599-7295 | — |
| Wayne Memorial Hospital, Incorporated | Goldsboro | North Carolina | 27534 | — |
| Kinston Medical Specialists | Kinston | North Carolina | 28501 | — |
| Rex Cancer Center at Rex Hospital | Raleigh | North Carolina | 27607 | — |
| Iredell Memorial Hospital | Statesville | North Carolina | 28677 | — |
| Wake Forest University Comprehensive Cancer Center | Winston-Salem | North Carolina | 27157-1096 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00588900, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 5, 2017 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00588900 live on ClinicalTrials.gov.